NEW YORK, April 13 - Recently, a number of genomics companies have announced bold new initiatives to use the genomics picks and shovels they market for their own drug discovery efforts.

But these companies may hit a drug discovery brick wall if they do not learn how to successfully negotiate the Food and Drug Administration approval phase, according to Attorney Edward Basile, a former FDA official who now heads the FDA practice group of Washington law firm King & Spalding.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.